Continuous low-dose cyclophosphamide plus prednisone in the treatment of relapsed and refractory multiple myeloma with severe complications

Background/objective We retrospectively analyzed the effective and safety of continuous low-dose cyclophosphamide combined with prednisone (CP) in relapsed and refractory multiple myeloma (RRMM) patients with severe complications. Methods A total of 130 RRMM patients with severe complications were enrolled in this study, among which 41 patients were further given bortezomib, lenalidomide, thalidomide or ixazomib on the basis of CP regimen (CP+X group). The response to therapy, adverse events (AEs), overall survival (OS) and progression-free survival (PFS) were recorded. Results Among the 130 patients, 128 patients received therapeutic response assessment, with a complete remission rate (CRR) and objective response rate (ORR) of 4.7% and 58.6%, respectively. The median OS and PFS time were (38.0 ± 3.6) and (22.9±5.2) months, respectively. The most common AEs were hyperglycemia (7.7%), pneumonia (6.2%) and Cushing’s syndrome (5.4%). In addition, we found the pro-BNP/BNP level was obviously decreased while the LVEF (left ventricular ejection fraction) was increased in RRMM patients following CP treatment as compared with those before treatment. Furthermore, CP+X regimen further improved the CRR compared with that before receiving the CP+X regimen (24.4% vs. 2.4%, P=0.007). Also, both the OS and PFS rates were significantly elevated in patients received CP+X regimen following CP regimen as compared with the patients received CP regimen only. Conclusion This study demonstrates the metronomic chemotherapy regimen of CP is effective to RRMM patients with severe complications.

[1]  A. Tafuri,et al.  Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group , 2022, EJHaem.

[2]  S. Srinivasan,et al.  Continuous lenalidomide and low‐dose dexamethasone in patients with transplant‐ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients , 2020, Cancer medicine.

[3]  P. Liu,et al.  Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study , 2020, Annals of Hematology.

[4]  A. Laganà,et al.  A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma , 2020, Leukemia & lymphoma.

[5]  M. Beksac,et al.  Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study , 2019, The Lancet.

[6]  F. Patriarca Frontline therapy in multiple myeloma: fast start for a long game. , 2019, The Lancet. Haematology.

[7]  E. Esin,et al.  Metronomic Chemotherapy: A Systematic Review of the Literature and Clinical Experience , 2019, Journal of oncology.

[8]  D. Hughes,et al.  Bortezomib consolidation post‐ASCT as frontline therapy for multiple myeloma deepens disease response and MRD‐negative rate whilst maintaining QOL and response to re‐treatment at relapse , 2018, British journal of haematology.

[9]  R. Raymakers,et al.  Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients , 2018, British journal of haematology.

[10]  C. Murray,et al.  On the road to universal health care in Indonesia, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2018, The Lancet.

[11]  C. Fitzmaurice,et al.  Global burden of multiple myeloma: A systematic analysis for the Global Burden of Disease study 2016. , 2018 .

[12]  M. Naghavi,et al.  Global Burden of Multiple Myeloma , 2018, JAMA oncology.

[13]  M. Dimopoulos,et al.  Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Sibel Naycı,et al.  The View of the Turkish Thoracic Society on the Report of the GOLD 2017 Global Strategy for the Diagnosis, Management, and Prevention of COPD. , 2017, Turkish thoracic journal.

[15]  A. Salihoglu,et al.  Clinical Outcomes Related to the Use of Bendamustine Therapy for Multiple Myeloma Patients Relapsed/Refractory to Immunomodulatory Drugs and Proteasome Inhibitors , 2017, Turkish journal of haematology : official journal of Turkish Society of Haematology.

[16]  D. Kazandjian Multiple myeloma epidemiology and survival: A unique malignancy. , 2016, Seminars in oncology.

[17]  S. Lonial,et al.  Integration of Novel Agents into the Care of Patients with Multiple Myeloma , 2016, Clinical Cancer Research.

[18]  P. Sonneveld,et al.  Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma. , 2016, Blood.

[19]  H. Goldschmidt,et al.  International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. , 2016, The Lancet. Oncology.

[20]  E. Vellenga,et al.  Combination therapy with bortezomib, continuous low‐dose cyclophosphamide and dexamethasone followed by one year of maintenance treatment for relapsed multiple myeloma patients , 2015, British journal of haematology.

[21]  Fan Zhou,et al.  持续口服小剂量环磷酰胺联合泼尼松治疗复发/难治性多发性骨髓瘤伴严重心功能不全患者疗效观察 , 2015, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi.

[22]  Fan Zhou,et al.  Continuous low-dose cyclophosphamide and prednisone in the treatment of relapsed/refractory multiple myeloma with severe heart failure , 2014, Leukemia & lymphoma.

[23]  I. Manițiu,et al.  Diagnostic and prognostic values of B-type natriuretic peptides (BNP) and N-terminal fragment brain natriuretic peptides (NT-pro-BNP) , 2013, Cardiovascular journal of Africa.

[24]  H. Goldschmidt,et al.  Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study , 2012, Leukemia.

[25]  J. Leonard,et al.  Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma , 2010, Cancer.

[26]  Robert A Kyle,et al.  Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. , 2009, Mayo Clinic proceedings.

[27]  Fan Zhou,et al.  Continuous administration of low-dose cyclophosphamide and prednisone as a salvage treatment for multiple myeloma. , 2009, Clinical lymphoma, myeloma & leukemia.

[28]  G. Koren,et al.  A Pilot Pharmacokinetic and Antiangiogenic Biomarker Study of Celecoxib and Low-dose Metronomic Vinblastine or Cyclophosphamide in Pediatric Recurrent Solid Tumors , 2006, Journal of pediatric hematology/oncology.

[29]  B. Barlogie,et al.  International uniform response criteria for multiple myeloma , 2006, Leukemia.

[30]  A. Hagenbeek,et al.  Continuous low-dose cyclophosphamide-prednisone is effective and well tolerated in patients with advanced multiple myeloma. , 2001, The Netherlands journal of medicine.

[31]  Gabriele Bergers,et al.  Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. , 2000, The Journal of clinical investigation.

[32]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.

[33]  P. L. Bergsagel,et al.  Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. , 2013, Mayo Clinic proceedings.

[34]  H. Goldschmidt,et al.  Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study , 2012, Leukemia.